Background {#Sec1}
==========

Thyroid hormone is essential for normal growth and neurologic development, particularly in the first few years of life, and hypothyroidism during this period is a leading cause of preventable intellectual disability worldwide. The implementation of universal newborn screening beginning in the 1970's has been an enormous public health success, virtually eradicating significant intellectual disability due to severe congenital hypothyroidism in the developed world. Following this early success, newborn screening programs have implemented increasingly stringent screening strategies over the past few decades. The resulting detection of milder cases of congenital hypothyroidism is the primary reason for the dramatic increase in the apparent incidence of congenital hypothyroidism from 1:4000 to 1:2000 newborns over the last 20--30 years \[[@CR1]--[@CR6]\]. However, unlike severe congenital hypothyroidism, for which the benefits of early detection and treatment are indisputable, uncertainty remains about mild disease in terms of the neurodevelopmental risk it poses and whether these risks are mitigated by treatment \[[@CR7]\]. Moreover, despite the prevalence of congenital hypothyroidism and our success in treating it, what causes most cases remains a mystery. This review discusses important recent developments in congenital hypothyroidism, focusing on our evolving understanding of its genetics, pathophysiology, and outcomes.

Primary congenital hypothyroidism {#Sec2}
---------------------------------

Most congenital hypothyroidism is caused by defects in the thyroid gland itself (primary hypothyroidism). Causes of primary congenital hypothyroidism can be broadly classified as failure of the thyroid gland to develop normally (*dysgenesis*) or failure of a structurally normal thyroid gland to produce normal quantities of thyroid hormone (*dyshormonogenesis*). Thyroid dysgenesis---which encompasses the spectrum of thyroid agenesis, hypoplasia, and ectopy---is the most common cause of congenital hypothyroidism, and its incidence (about 1:4000 infants) has not changed significantly over the last several decades \[[@CR3], [@CR5], [@CR6]\]. The underlying cause of thyroid dysgenesis, however, remains obscure in the vast majority of cases. Thyroid dysgenesis usually occurs sporadically, with only 2--5% of cases being attributable to identifiable genetic mutations (Fig. [1](#Fig1){ref-type="fig"}). Nevertheless, the known genetic causes of thyroid dysgenesis provide an important window into basic thyroid ontogeny. The thyroid-stimulating hormone receptor (*TSHR*) and the transcription factors *PAX8*, *NKX2--1*, and *FOXE1* are all expressed in the developing thyroid, and disruption of any of these genes can lead to failure of normal thyroid gland formation \[[@CR8]\]. These transcription factors also play important roles in other developing tissues, and mutations in each may be associated with additional syndromic features such as renal abnormalities (*PAX8*), interstitial lung disease and chorea (*NKX2--1*), or cleft palate, bifid epiglottis, choanal atresia, and spiky hair (*FOXE1*) (Table [1](#Tab1){ref-type="table"}).Fig. 1Genes associated with congenital hypothyroidism. TRH, thyrotropin-releasing hormone; TSH, thyroid-stimulating hormone; T4, thyroxine; T3, triiodothyronine Table 1Clinical features of genetic syndromes associated with congenital hypothyroidismPrimary congenital hypothyroidismCentral congenital hypothyroidism*PAX8*Renal abnormalities*IGSF1*Macro-orchidism, delayed pubertal testosterone rise, PRL deficiency, transient GH deficiency*NKX2--1*Interstitial lung disease, chorea*TBL1X*Hearing deficits*FOXE1*Cleft palate, bifid epiglottis, choanal atresia, spiky hair (Bamforth-Lazarus syndrome)*LEPR*Severe early-onset obesity, delayed puberty*NKX2--5*Congenital heart disease*POU1F1*Combined pituitary hormone deficiency*GLIS3*Neonatal diabetes mellitus, congenital glaucoma, developmental delay, hepatic fibrosis, polycystic kidneys*PROP1*Combined pituitary hormone deficiency*JAG1*Alagille syndrome (variable involvement of liver, heart, eye, skeletal, facial defects), congenital heart disease*HESX1*Combined pituitary hormone deficiency, optic nerve hypoplasia*SLC26A4*Sensorineural hearing loss*LHX3*Combined pituitary hormone deficiency, cervical abnormalities, sensorineural deafness*LHX4*Combined pituitary hormone deficiency, cerebellar abnormalities*SOX3*Combined pituitary hormone deficiency, craniofacial abnormalities*OTX2*Combined pituitary hormone deficiency, micro−/anophthalmia, seizures

Several other genes implicated in thyroid dysgenesis offer additional insights into the mechanisms of thyroid development. The transcription factor *NKX2--5* is expressed in the developing heart and thyroid, and *NKX2--5* mutations are associated with congenital cardiac abnormalities. Deletion of *NKX2--5* in mice causes thyroid agenesis, suggesting that this transcription factor plays an important role in thyroid development, but to what degree this finding extends to humans is not clear. Heterozygous variants in *NKX2--5* are found in some individuals with thyroid dysgenesis \[[@CR9], [@CR10]\]; however, the pathogenicity of these variants is unclear since they do not consistently cosegregate with thyroid disease in families \[[@CR9]\] and some may not impair protein function in vitro \[[@CR11]\]. Therefore, the precise role of *NKX2--5* in thyroid dysgenesis remains to be clarified \[[@CR8]\].

Mutations in *GLIS3* underlie a complex syndrome of congenital hypothyroidism, neonatal diabetes mellitus, and variable other abnormalities including congenital glaucoma, developmental delay, hepatic fibrosis, and polycystic kidneys \[[@CR12], [@CR13]\]. *GLIS3* is highly expressed in the thyroid, and congenital hypothyroidism in patients with *GLIS3* mutations may be associated with either thyroid dysgenesis or a eutopic but histologically abnormal thyroid gland \[[@CR13]\]. GLIS3 may act as a transcriptional activator or repressor, but its precise role in thyroid development and function remains to be determined. Some patients with *GLIS3* mutations require unusually high doses of levothyroxine to normalize serum thyroid stimulating hormone (TSH) levels \[[@CR13], [@CR14]\], which could imply an additional effect of GLIS3 on central regulation of the hypothalamic-pituitary-thyroid (HPT) axis.

Recently, genetic variants in *CDCA8* (also called *BOREALIN*) were identified in a study of three consanguineous families with thyroid dysgenesis \[[@CR15]\]. This gene is expressed in the thyroid and is known to play a key role in the chromosomal passenger complex that stabilizes the mitotic spindle during cell division. Interestingly, however, the *CDCA8* variants detected in these patients do not appear to affect mitosis but rather impair cell migration and adhesion in vitro. Thus, the potential mechanistic role of CDCA8 in thyroid dysgenesis is still unclear, and the range of thyroid phenotypes observed in patients carrying *CDCA8* variants is broad, ranging from thyroid agenesis or ectopy to euthyroid individuals with asymmetric thyroid lobes or thyroid nodules.

While thyroid dysgenesis remains the most common cause of congenital hypothyroidism, the incidence of dyshormonogenesis has been increasing over the last few decades. Whereas dyshormonogenesis accounted for only 15% of congenital hypothyroidism diagnosed in the early days of newborn screening, 30--40% of infants diagnosed by current newborn screening strategies have a eutopic thyroid gland consistent with a form of dyshormonogenesis \[[@CR3], [@CR5], [@CR6]\]. \[N.B. While the term *dyshormonogenesis* has classically referred to discrete defects in the cellular machinery of thyroid hormone synthesis leading to (often goitrous) congenital hypothyroidism, increasing recognition of the wide spectrum of severity of such defects makes it reasonable to define dyshormonogenesis as inadequate thyroid hormone production from a eutopic thyroid gland\].

Unlike thyroid dysgenesis, in which a monogenic cause is present in only a small minority of patients, dyshormonogenesis is frequently due to a genetic defect in some element of thyroid hormone synthesis. Known genetic causes of dyshormonogenesis include mutations in thyroglobulin (*TG*), thyroperoxidase (*TPO*), dual oxidase 2 (*DUOX2*) and its accessory protein (*DUOXA2*), the sodium-iodide symporter (*SLC5A5*), pendrin (*SLC26A4*), and iodotyrosine deiodinase (*IYD*) (Fig. [1](#Fig1){ref-type="fig"}). Although dual oxidase 1 (*DUOX1*) is highly homologous to *DUOX2*, isolated defects of *DUOX1* have not been reported to cause congenital hypothyroidism. However, because hypothyroidism due to *DUOX2* mutations tends to be relatively mild, it has been suggested that DUOX1 may partly compensate for DUOX2 deficiency. This hypothesis has been supported by the fact that mice lacking function of both DUOX enzymes have more severe hypothyroidism than those lacking only DUOX2 \[[@CR16]\]. More recently, the first evidence of a physiologic role for DUOX1 in humans was provided by a report of two siblings with homozygous inactivating mutations in both *DUOX1* and *DUOX2* associated with congenital hypothyroidism more severe than is typically observed in DUOX2 deficiency alone \[[@CR17]\]. While further data are needed, it appears that DUOX1 may indeed serve a redundant role in the human thyroid, not being required for thyroid function under normal circumstances but able to partly compensate when DUOX2 function is impaired.

Despite the growing number of genes associated with congenital hypothyroidism, precisely what proportion of congenital hypothyroidism is attributable to known genetic causes and the relative prevalence of mutations in specific genes are not known precisely, and estimates vary among studies. These variations are influenced by several factors including cohort selection that differs in terms of patient ethnicity and the type(s) of congenital hypothyroidism studied, and the sequencing approaches used to detect mutations. With regard to ethnicity, for example, *DUOX2* appears to be the most commonly implicated gene in East Asian populations, with *DUOX2* variants reported in 16--32% of congenital hypothyroidism patients in Korea, Japan, and China \[[@CR18]--[@CR20]\]. On the other hand, in a cohort of mostly European and Middle Eastern patients, variants in *TG* were much more common (55%) than *DUOX2* variants, which were found in only 18% \[[@CR21]\]. However, the latter study was enriched for familial cases of congenital hypothyroidism and is likely to overestimate the prevalence of genetic mutations; therefore, the reported prevalences are likely not generalizable to sporadic cases, which constitute the majority of congenital hypothyroidism seen in clinical practice.

This demographic difference highlights the important influence of cohort selection on the apparent prevalence of genetic mutations in congenital hypothyroidism. Another illustration comes from studies that include patients with congenital hypothyroidism of varying etiologies. For example, one Korean study of 170 infants with congenital hypothyroidism of any etiology found mutations in 31% (most of whom had dyshormonogenesis) \[[@CR18]\], while another study from the same country that included only patients with a eutopic thyroid gland identified mutations in 53.5% \[[@CR22]\]. Similarly, the prevalence of *DUOX2* variants in Italy has been reported as 15% in unselected patients with congenital hypothyroidism, 23% in those with a eutopic thyroid gland \[[@CR23]\], and to 30--37% in those with a eutopic gland and a documented partial iodine organification disorder \[[@CR24], [@CR25]\]. Thus, more refined cohort selection can significantly increase the observed prevalence of variants in relevant genes and must be considered when interpreting these data.

Finally, as might be expected, recent studies examining larger sets of candidate genes (often using next-generation sequencing techniques) are increasingly identifying potentially causative variants in a higher proportion of patients than older studies that analyzed only one or a few genes. For example, a recent analysis of 11 genes associated with congenital hypothyroidism in 177 Italian patients with congenital hypothyroidism of any cause demonstrated an overall variant prevalence of 58%; the prevalence was even higher (about 75%) in patients with a eutopic thyroid gland \[[@CR23]\]. Many patients (23%) harbored variants in more than one gene, similar to other reports \[[@CR18], [@CR20], [@CR22], [@CR26]\]. This consistent finding suggests that the apparent lack of heritability of congenital hypothyroidism may be explained by a confluence of rare variants in several genes. On the other hand, while this hypothesis is intriguing, it remains at odds with the observed high rate of discordance for thyroid dysgenesis among monozygotic twins (who share nearly all variants in all genes) \[[@CR27]\], which implies that it is unlikely for a significant proportion of congenital hypothyroidism to be explained by germline genetic changes alone. Another limitation of this and similar genetic studies is that the functional significance of many reported variants---particularly novel missense variants---has not been rigorously evaluated; accordingly, a causal role for these variants in congenital hypothyroidism must be imputed cautiously.

Another novel aspect of this study was to analyze variants in genes associated with both thyroid dysgenesis and dyshormonogenesis in all patients, regardless of their thyroid anatomy. Somewhat unexpectedly, variants in genes typically associated with dysgenesis (e.g., *NKX2--1*, *FOXE1*) were found in patients with dyshormonogenesis, and vice versa \[[@CR23]\]. This finding highlights the potential overlap in pathogenesis between the classically distinct phenotypes of thyroid dysgenesis and dyshormonogenesis. An example of such cross-over is *JAG1*, which encodes a ligand of the Notch receptor that is critical for normal thyroid gland formation in zebrafish \[[@CR28]\]. Recently, anatomic thyroid defects have been found in a series of patients with heterozygous *JAG1* variants, including both patients with classical Alagille syndrome (a multisystem disorder known to be caused by *JAG1* mutations) and patients with congenital hypothyroidism without syndromic features \[[@CR29]\]. These variants were confirmed to disrupt JAG1 function in vivo and strongly support a role for JAG1 in thyroid development in humans. Interestingly, however, the etiologies of hypothyroidism in patients with *JAG1* mutations included not only thyroid dysgenesis, as might be expected from the zebrafish model, but also eutopic thyroid glands. Thus, the case of *JAG1* illustrates the complexity of thyroid development and that the genetic abnormalities underlying the phenotypes of thyroid dysgenesis and dyshormonogenesis may overlap to a greater extent than has been previously appreciated.

Central congenital hypothyroidism {#Sec3}
---------------------------------

In contrast to primary disorders of the thyroid gland, central hypothyroidism is caused by dysfunction of hypothalamic or pituitary control of the thyroid axis that leads to inadequate production and/or bioactivity of TSH. Congenital hypothyroidism of central origin is rare: early estimates of its incidence were between 1:29,000 and 1:110,000 \[[@CR30]--[@CR32]\], although more recent data from the Netherlands suggest that it may occur in as many as 1:16,000 newborns and could represent up to 13% of cases of permanent congenital hypothyroidism \[[@CR33], [@CR34]\]. Although this incidence is similar to that of phenylketonuria (1:15,000) \[[@CR35]\]---the condition for which newborn screening was originally introduced in the 1960's---central congenital hypothyroidism cannot be detected by the TSH-based screening strategies used by the majority of the newborn screening programs worldwide \[[@CR1]\]. Central hypothyroidism may be detected by screening programs that measure T4 concentrations in all infants, along with measurement of TSH either simultaneously or in the subset of infants with low T4. However, this approach may not have optimal sensitivity and may miss some cases of central hypothyroidism \[[@CR36]\].

One argument that has been made against routine screening for central hypothyroidism is that it tends to be milder than primary hypothyroidism and is therefore less critical to identify and treat early. Although developmental delays have been reported in small studies of infants who experienced delayed treatment of central congenital hypothyroidism \[[@CR36], [@CR37]\], there are no data to demonstrate clearly that early treatment improves outcomes in infants with this condition. However, indirect evidence may be derived from studies of primary congenital hypothyroidism, in which the initial serum concentration of total or free thyroxine (FT4) is one of the most important and consistent predictors of neurodevelopmental outcome \[[@CR37]--[@CR40]\]. In light of this, the premise that central congenital hypothyroidism poses less developmental risk has been challenged by a recent study from the Netherlands demonstrating that 55% of newborns with central hypothyroidism detected on newborn screening had FT4 concentrations sufficiently low (\< 10 pmol/L) to warrant treatment according to current consensus guidelines \[[@CR41], [@CR42]\]. While few of these patients had the severely low FT4 levels often seen in primary congenital hypothyroidism, their FT4 levels were reduced to a range (5--10 pmol/L) that has been associated with modest deficits at age 10 years \[[@CR37]\]. Thus, it appears that a substantial proportion of infants with central congenital hypothyroidism may be at some developmental risk if undetected and untreated, although the precise extent of this risk remains to be determined.

In addition, 75% of infants with central congenital hypothyroidism have additional, potentially life-threatening pituitary hormone deficiencies such as adrenal insufficiency and growth hormone deficiency \[[@CR34]\], and detection of these comorbidities represents another argument in favor of screening for central hypothyroidism. Moreover, some have suggested that a carefully designed T4-based screening strategy able to detect these infants may actually be more cost effective than TSH-based screening \[[@CR33]\]. In summary, while arguments can be made for routine newborn screening for central hypothyroidism, more compelling evidence is needed to support the need for and feasibility of widespread implementation of such strategies.

Despite its rarity, central congenital hypothyroidism provides an important window into the ontology and physiology of the HPT axis. Normally, thyrotropin-releasing hormone (TRH) from the hypothalamus stimulates thyrotropes in the anterior pituitary to secrete TSH. Congenital defects in this system result from abnormal development of the hypothalamus or pituitary or from genetic alterations that impair the function of TRH or TSH. Developmental or structural anomalies often have broad effects on the hypothalamus and/or pituitary that lead to deficits in multiple pituitary hormones. While some of these cases have no identifiable genetic basis, others can be attributed to mutations in one of several genes critical for the normal early development of these structures, including *HESX1*, *LHX3*, *LHX4*, *SOX3*, and *OTX2* (Fig. [1](#Fig1){ref-type="fig"}). These transcription factors have broad effects on fetal development and each is associated with particular syndromic features in addition to combined pituitary hormone deficiency (Table [1](#Tab1){ref-type="table"}). In contrast, the transcription factors *PROP1* and *POU1F1* are expressed later in anterior pituitary differentiation and their disruption results in combined pituitary hormone deficiency without other syndromic features \[[@CR43]\].

While central developmental abnormalities often affect multiple pituitary hormones, specific defects in TRH or TSH signaling lead to isolated central congenital hypothyroidism. Until recently the only known genetic causes of this condition were very rare mutations in the TRH receptor (*TRHR*) \[[@CR44], [@CR45]\] or the TSH β-subunit (*TSHB*) \[[@CR26]\]. However, in 2012 a study of 11 families with central congenital hypothyroidism identified a novel X-linked cause of central hypothyroidism, *IGSF1* \[[@CR46]\]. Numerous cases of IGSF1 deficiency have since been described, making it the most common identifiable genetic cause of isolated central congenital hypothyroidism \[[@CR47]\].

In addition to central hypothyroidism, males carrying an inactivating mutation of *IGSF1* manifest a clinical syndrome that includes macro-orchidism (88% of patients) and variable hypoprolactinemia (60% of patients). Testicular enlargement can begin before the onset of puberty and has been observed as early as 3 years of age, and affected adults may have testicular volumes up to 45--50 mL. While the normal pubertal increase in testicular size is accelerated in affected individuals, the pubertal rise in testosterone levels appears to be delayed, and plasma testosterone levels remain in the low-normal range in adults. A few children also appear to have transient growth hormone deficiency that resolves by adulthood. Importantly, although the IGSF1 deficiency syndrome is X-linked, 18% of female mutation carriers have central hypothyroidism, about 20% have biochemical prolactin deficiency (although lactation is apparently normal), and up to one-third have late menarche \[[@CR48], [@CR49]\].

At the time of its discovery *IGSF1* was known to encode a plasma membrane glycoprotein expressed in anterior pituitary thyrotropes, but its function was unknown. Recently, two studies have begun to elucidate the role of *IGSF1* in the HPT axis and a potential mechanism by which it may cause central hypothyroidism \[[@CR50], [@CR51]\]. Both humans and mice deficient in IGSF1 show impaired secretion of TSH in response to exogenous TRH administration, implying a functional defect in TRH signaling. Further studies indicate that IGSF1 directly stimulates TRHR activity in cell culture \[[@CR50]\], while Igsf1-deficient mice have reduced pituitary TRHR expression and increased hypothalamic TRH expression \[[@CR51]\]. Thus, both in vitro and in vivo evidence suggest that IGSF1 deficiency may cause central hypothyroidism by impairing expression and downstream signaling of the TRH receptor in pituitary thyrotropes. One mechanism by which IGSF1 may promote TRHR signaling is by blocking the inhibitory effect of TGFβ on TRHR expression \[[@CR50]\]. Absence of IGSF1 may permit excessive TGFβ-mediated suppression of TRHR that leads to central hypothyroidism. Interestingly, IGSF1 appears to have the opposite effect in pituitary gonadotropes of decreasing FSH β-subunit (*FSHB*) expression. Loss of this inhibition and consequent oversecretion of FSH might explain the macro-orchidism observed in males with IGSF1 deficiency. IGSF1 is also expressed in the Leydig cells and germ cells of the testis, where its role remains uncertain \[[@CR50]\]. While more research is needed to understand the mechanisms of IGSF1 action, its discovery has opened the door to the study of novel biology in both the thyroid and gonadal axes.

Recently, mutations in *TBL1X* have been found in several families with X-linked central hypothyroidism \[[@CR52]\]. This gene is expressed in the human pituitary and the paraventricular nucleus of the hypothalamus (where TRH-secreting neurons are located), and it encodes a protein that is part of the NCoR-SMRT corepressor complex, a key regulator of thyroid hormone-dependent gene expression. A pathogenic role for TBL1X defects is supported by a mouse model in which impaired NCoR function causes central hypothyroidism \[[@CR53]\], and further investigation of the potential role of *TBL1X* in central hypothyroidism is now needed.

Mild congenital hypothyroidism {#Sec4}
------------------------------

As previously noted, most newborn screening programs around the world use TSH-based strategies that effectively detect the vast majority of congenital hypothyroidism \[[@CR1]\]. Over the past 30 years, many programs have lowered their screening TSH cut-offs from 20 - 50 mIU/L to 6--15 mIU/L. These changes have resulted in the diagnosis of many more patients with mild congenital hypothyroidism, most of whom have a eutopic thyroid gland \[[@CR3], [@CR4]\]. However, in contrast to the known neurodevelopmental risks of severe congenital hypothyroidism and the obvious benefits conferred by its timely and adequate treatment, much less is known about the risks posed by the milder forms of congenital hypothyroidism that are increasingly being diagnosed \[[@CR7]\]. This uncertainty is reflected in current consensus guidelines, which find insufficient evidence to recommend for or against the treatment of infants with persistent modest TSH elevation (6--20 mIU/L in serum) but normal levels of FT4 \[[@CR42]\]. Therefore, further defining the risks and appropriate treatment of mild congenital hypothyroidism is important, but a randomized, controlled trial to resolve this issue may be difficult to accomplish given the prevailing bias (and perhaps the ethical duty) not to withhold treatment from these infants \[[@CR42]\].

Several recent studies have attempted to address this question. A series of studies in Belgian children that assessed the relationship between newborn screening TSH concentrations and various neurodevelopmental outcomes found no relationship between mild TSH elevation (up to 15 mIU/L) and cognitive or psychomotor development or parent-reported behavior scores at 4--6 years of age \[[@CR54]--[@CR56]\]. However, the power of these studies to detect differences in outcomes was limited by the small number of patients with elevated TSH concentrations, particularly in the 10--15 mIU/L range.

A different conclusion was reached by an Australian study that linked newborn screening results with standardized national assessments of childhood development and school performance \[[@CR57]\]. This population-based analysis of over 500,000 children found that the risk of poor educational or developmental outcome rose continuously with increasing newborn screening TSH concentration from the 75th to the 99.9th percentile, even after adjusting for potential confounders. Interestingly, no increased risk was observed among infants with screening TSH levels above the 99.9th percentile (12--14 mIU/L), perhaps due to these patients being diagnosed with and treated for congenital hypothyroidism. This study has limitations, including the lack of many patient-level details (including the possibility of diagnosis and treatment of congenital hypothyroidism), inability to account for the potential confounding effect of iodine deficiency, and the inability to establish causality from the observational study design. Nevertheless, the results suggest that mild congenital hypothyroidism may be associated with identifiable neurodevelopmental risks.

Despite the unresolved question of whether infants with mild congenital hypothyroidism benefit from treatment, detecting mild TSH elevations on newborn screening may have other advantages. In particular, a proportion of infants with mild TSH elevation at screening may actually have congenital hypothyroidism that requires treatment. For example, about 12% of infants confirmed to have permanent congenital hypothyroidism---including both dysgenesis and dyshormonogenesis---have only mild TSH elevation at screening \[[@CR3]--[@CR5]\]. Conversely, among infants with mild initial TSH elevation, between 3% and 30% (depending on the specific cut-off used) prove to have permanent congenital hypothyroidism \[[@CR58], [@CR59]\]. In a substantial number of these patients, TSH concentrations are much higher when measured in the confirmatory serum sample than was suggested by an initial mild abnormality that would be missed by a higher TSH cut-off \[[@CR4], [@CR59]\]. This issue may be particularly significant in preterm and low birth-weight infants with congenital hypothyroidism, in whom the TSH rise may be delayed \[[@CR60]\]. Still, these potential advantages of lower TSH cut-offs come at the expense of increased costs of screening, increased parental anxiety over abnormal results of uncertain significance, and the potential for overtreatment with levothyroxine, which itself may be associated with adverse neurodevelopmental outcomes \[[@CR61]\]. Thus, in light of currently available data, the true balance of benefits and costs derived from more stringent screening thresholds continues to be debated \[[@CR62]\].

Conclusions {#Sec5}
===========

The past 50 years have witnessed extraordinary advancements in the diagnosis, treatment, and outcomes of patients with congenital hypothyroidism. While we still do not understand what causes the majority of congenital hypothyroidism, increasing evidence suggests that a complex interplay of genetic variants in multiple thyroid-related genes may be involved, and the ongoing search for novel genetic causes continues to shed new light on the development and physiology of the hypothalamic-pituitary-thyroid axis. Meanwhile, strong evidence is lacking to guide the management of patients with mild congenital hypothyroidism who have increasingly been diagnosed in recent years. Further high-quality studies are needed to assess the neurodevelopmental risks to these infants and to what extent they may benefit from treatment.
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